Primary Tumor (same for clinical and pathologic classification)
|
TX |
primary tumor cannot be assessed |
|
T0 |
no evidence of primary tumor |
|
Tis |
carcinoma in situ |
|
Tis(DCIS) |
ductal carcinoma in situ |
|
Tis(LCIS) |
lobular carcinoma in situ |
|
Tis(Paget) |
Paget disease of the nipple with no tumor |
|
T1 |
tumor 2 cm or less in greatest dimension |
|
T1mic |
microinvasion 0.1 cm or less in greatest dimension |
|
T1a |
tumor >0.1 cm but not >0.5 cm in greatest |
|
dimension |
|
|
T1b |
tumor >0.5 cm but not >1 cm in greatest |
|
dimension |
|
|
T1c |
tumor >1 cm but not >2 cm in greatest dimension |
|
T2 |
tumor >2 cm but not >5 cm in greatest dimension |
|
T3 |
tumor >5 cm in greatest dimension |
|
T4 |
tumor of any size with direct extension to chest wall or skin |
|
T4a |
extension to chest wall but not including pectoral muscle |
|
T4b |
edema (peau d'orange) or ulceration of the skin of the breast, or satellite skin nodules confined to the same breast |
|
T4c |
both T4a and T4b |
|
T4d |
inflammatory carcinoma |
Regional Lymph Node (pathologic, pN)
|
pNX |
regional lymph nodes cannot be assessed (previously removed or not excised) |
|
pN0 |
No regional lymph node metastasis histologically; no additional examination for isolated tumor cells (ITC) |
|
pN0(i-) |
No regional lymph node metastasis histologically, negative immunohistochemical (IHC) studies |
|
pN0(i+) |
No regional lymph node metastasis histologically, positive IHC, no IHC cluster >0.2 mm |
|
pN0(mol-) |
No regional lymph node metastasis histologically; negative molecular findings (reverse transcriptase/polymerase chain reaction, RT-PCR) |
|
pN0(mol+) |
No regional lymph node metastasis histologically; positive molecular reaction (RT-PCR) |
|
pN1 |
metastasis in 1 to 3 axillary lymph nodes and/or internal mammary lymph nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent (not detected by imaging studies or clinical examination) |
|
pN1mi |
micrometastasis (>0.2 mm, none >2.0 mm) |
|
pN1a |
metastasis in 1 to 3 axillary lymph nodes |
|
pN1b |
metastasis in internal mammary lymph nodes with microscopic disease detected by sentinel lymph node but not clinically apparent (not detected by imaging studies or clinical examination) |
|
pN1c |
metastasis in 1 to 3 axillary lymph nodes and in internal mammary lymph nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent (not detected by imaging studies or clinical examination). If associated with >3 positive axillary lymph nodes, the internal mammary nodes are classified as pN3b |
|
pN2 |
metastasis in 4 to 9 axillary lymph nodes, or in clinically apparent internal mammary lymph nodes in the absence of axillary lymph node metastasis |
|
pN2a |
metastasis in 4 to 9 axillary lymph nodes (at least one tumor deposit >2.0 mm) |
|
pN2b |
metastasis in clinically apparent (detected by imaging studies, excluding lymphoscintigraphy or clinical examination) internal mammary lymph nodes in the absence of axillary lymph node metastasis |
|
pN3 |
metastasis in 10 or more axillary lymph nodes, or in infraclavicular lymph nodes, or in clinically apparent ipsilateral internal mammary lymph nodes in the presence of 1 or more positive axillary lymph node; or in >3 axillary lymph nodes with clinically negative microscopic metastasis in internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes |
|
pN3a |
metastasis in 10 or more axillary lymph nodes (at least one tumor deposit >2.0 mm), or metastasis to the infraclavicular lymph nodes |
|
pN3b |
metastasis in clinically apparent ipsilateral mammary lymph nodes in the presence of 1 or more positive axillary lymph nodes; or in >3 axillary lymph nodes and in internal mammary lymph nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent |
|
pN3c |
metastasis in ipsilateral supraclavicular lymph nodes |
|
(sn) = sentinel lymph node |
|
|
If surgery occurs after the patient has received neoadjuvant chemotherapy, hormonal therapy, immunotherapy, or radiation therapy, the prefix “y” is used with the TNM classification |
|
Distant Metastasis
|
MX |
distant metastasis cannot be assessed |
||
|
M0 |
no distant metastasis |
||
|
M1 |
distant metastasis |
||
|
Stage 0 |
Tis |
N0 |
M0 |
|
Stage I |
T1 |
N0 |
M0 |
|
Stage IIA |
T0 |
N1 |
M0 |
|
T1 |
N1 |
M0 |
|
|
T2 |
N0 |
M0 |
|
|
Stage IIB |
T2 |
N1 |
M0 |
|
T3 |
N0 |
M0 |
|
|
Stage IIIA |
T0 |
N2 |
M0 |
|
T1 |
N2 |
M0 |
|
|
T2 |
N2 |
M0 |
|
|
T3 |
N1 |
M0 |
|
|
T3 |
N2 |
M0 |
|
|
Stage IIIB |
T4 |
N0 |
M0 |
|
T4 |
N1 |
M0 |
|
|
T4 |
N2 |
M0 |
|
|
Stage IIIC |
Any T |
N3 |
M0 |
|
Stage IV |
Any T |
Any N |
M0 |